MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

Documenti analoghi

• Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem cell–like Properties in Cancer Cells
  di: Shien, Kazuhiko, et al.
  Pubblicazione: (2013)
• Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
  di: Gandhi, Jeet, et al.
  Pubblicazione: (2009)
• TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
  di: Hiroki Otani, et al.
  Pubblicazione: (2015-01-01)
• TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells
  di: Otani, Hiroki, et al.
  Pubblicazione: (2015)
• Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis
  di: Toyooka, Shinichi, et al.
  Pubblicazione: (2012)